{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:23:21Z","timestamp":1783445001326,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ajo.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:30:09Z","timestamp":1776015009000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association Between PDE-5 Inhibitor Therapy and the Hazard of Open-Angle Glaucoma"],"prefix":"10.1016","volume":"288","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-375X","authenticated-orcid":false,"given":"ABDELRAHMAN M.","family":"ELHUSSEINY","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7014-1760","authenticated-orcid":false,"given":"IBRAHIM","family":"ABBOUD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7500-0731","authenticated-orcid":false,"given":"AMR","family":"ALMOBAYED","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-2720","authenticated-orcid":false,"given":"FELIPE A.","family":"MEDEIROS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ajo.2026.04.009_bib0001","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2026.04.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101223","article-title":"Advances in understanding glaucoma pathogenesis: a multifaceted molecular approach for clinician scientists","volume":"94","author":"Ekici","year":"2023","journal-title":"Mol Aspects Med"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.009_bib0003","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.009_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1350-9462(02)00008-3","article-title":"The impact of ocular blood flow in glaucoma","volume":"21","author":"Flammer","year":"2002","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.ajo.2026.04.009_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/IJG.0000000000000981","article-title":"New recommendations for the treatment of systemic hypertension and Their potential implications for glaucoma management","volume":"27","author":"De Moraes","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ajo.2026.04.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2023.101217","article-title":"Neurovascular dysfunction in glaucoma","volume":"97","author":"Alarcon-Martinez","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.04.009_bib0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajo.2023.03.032","article-title":"Increased risks of open-angle glaucoma in untreated hypertension","volume":"252","author":"Lee","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2023.03.014","article-title":"A systematic review and meta-analysis of systemic antihypertensive medications with intraocular pressure and glaucoma","volume":"255","author":"Leung","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.009_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/IJG.0000000000001964","article-title":"Multiple systemic vascular risk factors are associated with low-tension glaucoma","volume":"31","author":"Funk","year":"2022","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.009_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/bjo-2023-325035","article-title":"Association between metformin use with circumpapillary retinal nerve fibre layer thickness and capillary vessel density in glaucoma","volume":"109","author":"Nishida","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajo.2025.04.003","article-title":"Racial and ethnic differences in the association between Statin use and the risk of ocular hypertension and open-angle glaucoma","volume":"276","author":"Elhusseiny","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0012","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2025.07.014","article-title":"Association between chronic oral nitrate use and the risk of ocular hypertension and open-angle glaucoma","volume":"279","author":"Elhusseiny","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.04.009_bib0013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the European Eye Epidemiology Consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.009_bib0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1043-2760(98)00127-1","article-title":"Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor","volume":"10","author":"Moreland","year":"1999","journal-title":"Trends Endocrinol Metab"},{"issue":"22","key":"10.1016\/j.ajo.2026.04.009_bib0015","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.jacc.2011.09.086","article-title":"Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection","volume":"59","author":"Kukreja","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.ajo.2026.04.009_bib0016","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.009_bib0017","article-title":"Phosphodiesterase 5 Inhibitors for Pulmonary Hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.009_bib0018","article-title":"Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon","volume":"11","author":"Maltez","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajo.2026.04.009_bib0019","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2012.00167","article-title":"PDE5 inhibitors as potential tools in the treatment of cystic fibrosis","volume":"3","author":"Noel","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0020","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ajo.2026.04.009_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1019187","article-title":"Inhibition of Phosphodiesterase: a novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease","volume":"14","author":"Sheng","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2026.04.009_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000486105","article-title":"Treatment of macular degeneration with sildenafil: results of a two-year trial","volume":"240","author":"Coleman","year":"2018","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.009_bib0023","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1755-3768.2011.02305.x","article-title":"Measurement of choroidal perfusion and thickness following systemic sildenafil (Viagra(\u00ae))","volume":"91","author":"Kim","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.009_bib0024","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0420.2005.00422.x","article-title":"The effects of sildenafil on ocular blood flow","volume":"83","author":"Koksal","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"issue":"11","key":"10.1016\/j.ajo.2026.04.009_bib0025","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1167\/iovs.03-0177","article-title":"Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects","volume":"44","author":"Polak","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.04.009_bib0026","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9394(00)00375-5","article-title":"No clinically important effects on intraocular pressure after short-term administration of sildenafil citrate (Viagra)","volume":"129","author":"Yajima","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/DDDT.S186633","article-title":"Ocular Side effects of Levitra\u00ae (vardenafil) - results of a double-blind crossover study in healthy male subjects","volume":"13","author":"Roessler","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.ajo.2026.04.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e554","article-title":"Ocular Safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension","volume":"344","author":"Wirostko","year":"2012","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ajo.2026.04.009_bib0029","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/archophthalmol.2009.36","article-title":"Retinal effects of 6 months of daily use of tadalafil or sildenafil","volume":"127","author":"Cordell","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"9596","key":"10.1016\/j.ajo.2026.04.009_bib0030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for Reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.009_bib0031","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0420.2006.00803.x","article-title":"Acute angle-closure glaucoma following sildenafil citrate-aided sexual intercourse","volume":"85","author":"Ramasamy","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"8","key":"10.1016\/j.ajo.2026.04.009_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183388","article-title":"Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the united states","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2026.04.009_bib0033","first-page":"211","article-title":"Histopathologic Effect of Chronic Use of Sildenafil Citrate on the Choroid & Retina in Male Rats","volume":"117","author":"Vatansever","year":"2003","journal-title":"Indian J Med Res"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.009_bib0034","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/IAE.0b013e3181eef0ae","article-title":"The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography","volume":"31","author":"Vance","year":"2011","journal-title":"Retina"},{"issue":"Pt 4","key":"10.1016\/j.ajo.2026.04.009_bib0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/eye.2001.163","article-title":"Effect of sildenafil on ocular haemodynamics","volume":"15","author":"D\u00fcndar","year":"2001","journal-title":"Eye (Lond)"},{"issue":"22","key":"10.1016\/j.ajo.2026.04.009_bib0036","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJM200006013422218","article-title":"Sildenafil and ocular perfusion","volume":"342","author":"Sponsel","year":"2000","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2026.04.009_bib0037","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/jamaophthalmol.2015.5601","article-title":"Association of dietary nitrate intake with primary open-angle glaucoma: a prospective analysis from the nurses' Health study and health professionals follow-up study","volume":"134","author":"Kang","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2026.04.009_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2025.110778","article-title":"Altered biopterin-related cofactor metabolism in the aqueous humor of glaucoma patients","volume":"263","author":"Zemitis","year":"2026","journal-title":"Exp Eye Res"},{"issue":"9150","key":"10.1016\/j.ajo.2026.04.009_bib0039","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(98)05473-7","article-title":"Retinal side-effects of sildenafil","volume":"353","author":"Vobig","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.009_bib0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0002-9394(00)00944-2","article-title":"Effect of sildenafil citrate (Viagra) on the ocular circulation","volume":"131","author":"Grunwald","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2026.04.009_bib0041","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0002-9394(01)01268-5","article-title":"Acute effects of sldenafil citrate (Viagra) on intraocular pressure in open-angle glaucoma","volume":"132","author":"Grunwald","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.04.009_bib0042","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1385\/AO:37:2:085","article-title":"No effects of long-term sildenafil treatment on ocular functions","volume":"37","author":"Oguz","year":"2005","journal-title":"Ann Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426002047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:27:12Z","timestamp":1783441632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426002047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S0002939426002047"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.009","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between PDE-5 Inhibitor Therapy and the Hazard of Open-Angle Glaucoma","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}